Injectable division
CagriSema
AClass-leading
Novo Nordisk · certified
vs
Injectable division
Tirzepatide (Zepbound)
Class-leadingA
Eli Lilly · approved
17%
Efficacy
a hair ahead · 18%
Mild (+2.3)
Tolerability
Mild (+3.6)
Subcutaneous injection
Route
Subcutaneous injection
None
Food / water rule
None
Refrigerated
Storage
Refrigerated (room temperature up to 21 days)
The call: Two class-leaders, effectively tied on both axes: frontier efficacy, mild tolerability. The numbers put them within a point of each other, which the tiers are built to absorb. The real separators are outside this table: tirzepatide is approved and shipping, CagriSema is certified but still awaiting its decision.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Winners are called only across a tier or band boundary; within one, the drugs are effectively tied. The side marked leads or gentler wins that axis.
CagriSema verdict · Tirzepatide verdict · How this is scored